Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia

Metabolism: Clinical and Experimental

Volumn 47, Issue 9, 1998, Pages 1097-1104

  Knopp, R H ^a   Alagona, P ^b   Davidson, M ^b   Goldberg, A C ^b   Kafonek, S D ^b   Kashyap, M ^b   Sprecher, D ^b   Superko, H R ^b   Jenkins, S ^b   Marcovina, S ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; FLUSHING; HYPERLIPIDEMIA; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION;

EID: 2442425776     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90284-0     Document Type: Article

References (33)

1. National Cholesterol Education Program Expert Panel: Summary of the second report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269:3015-3023, 1993
2. Luria MH: Effect of low-dose niacin on high-density lipoprotein cholesterol and total cholesterol/high-density lipoprotein cholesterol ratio. Arch Intern Med 148:2493-2495, 1988
3. McKenney JM, Proctor JD, Harris S, et al: A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 271:672-677, 1994
4. Carlson LA, Hamsten A, Asplund A: Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidemic subjects treated with nicotinic acid. J Intern Med 226:271-276, 1989
5. Canner PL, Berge KG, Wenger NK, et al: Fifteen year mortality on Coronary Drug Project patients: Long-term treatment with niacin. J Am Coll Cardiol 8:1245-1255, 1986
6. Blankenhorn DH, Nessim SA, Johnson RL: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary bypass grafts. JAMA 257:3233-3240, 1987
7. Knopp R, Ginsberg J, Albers JJ: Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 34:642-650, 1985
8. Keenan JM, Fontaine PL, Wenz JB, et al: Niacin revisited: A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med 151:1424-1432, 1991
9. Squires RW, Allison TG, Gau GT, et al: Low-dose, time-release nicotinic acid: Effects in selected patients with low concentrations of high density lipoprotein cholesterol. Mayo Clin Proc 67:855-860, 1992
10. Schlierf G, Dorow E: Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis. J Clin Invest 52:732-740, 1973
11. Schlierf G, Hess G: Inhibition of carbohydrate-induced hypertriglyceridemia by nicotinic acid. Artery 3:174-179, 1977
12. Kruse W, Kruse W, Raetzer H, et al: Nocturnal inhibition of lipolysis in man by nicotinic acid and derivatives. Clin Pharmacol 16:11-15, 1979
13. 2+ precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin Chem 28:1279-1288, 1982
14. Bachorik PS, Albers JJ: Precipitation methods for quantitation of lipids, in Albers JJ, Segrest JP (eds): Methods in Enzymology. Orlando, FL, Academic, 1986, pp 78-100
15. Marcovina SM, Albers JJ, Henderson LO, et al: International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apo A-I values by the use of international reference material. Clin Chem 39:773-781, 1993
16. Marcovina SM, Albers JJ, Kennedy H, et al: International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apo B by the use of international reference material. Clin Chem 40:586-592, 1994
17. Marcovina SM, Albers JJ, Gabel B, et al: The effect of the number of apo(a) kringle 4 domains on the imniunochemical measurement of Lp(a). Clin Chem 41:246-255, 1995
18. Applebaum-Bowden D, McLean P, Steinmetz A, et al: Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women. J Lipid Res 30:1895-1906, 1989
19. Sniderman AD, Cianflone K: Substrate delivery as a determinant of hepatic apoB secretion. Arterioscler Thromb 13:629-636, 1993
20. Kwiterovich PO, Motevalli M, Miller M, et al: Further insights into the pathophysiology of hyperapobetalipoproteinemia. Clin Chem 37:317-326, 1991
21. Venkatesan S, Cullen P, Pacy P, et al: Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia. Arterioscler Thromb 13: 1110-1118, 1993
22. Austin MA, King MC, Vranizan KM, et al: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 82:495-506, 1990
23. Brunzell JD, Albers JJ, Chait A, et al: Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 24:147-155, 1983
24. Kwiterovich PO, White S, Forte T, et al: Hyperapobetalipoproteinemia in a kindred with familial combined hyperlipidemia and familial hypercholesterolemia. Arterioscler Thromb 7:211-225, 1987
25. Williams RR, Hunt SC, Hopkins PN, et al: Familial dyslipidemia hypertension: Evidence from 58 Utah families for a syndrome present in approximately 15% of patients with essential hypertension. JAMA 259:3579-3586, 1988
26. Reaven GM: Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
27. Superko HR, Krauss RM: Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 95:69-76, 1992
28. Morgan JM, Capuzzi DM, Guyton JR, et al: Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial. J Cardiovasc Pharmacol Therapeut 1:195-202, 1996
29. Davignon J, Roederer G, Montigny M, et al: Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 73:339-345, 1994
30. Stein EA, Davidson MH, Dujovne CA, et al: The efficacy and tolerability of low dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: A prospective trial. J Cardiovasc Pharmacol Therapeut 1:107-116, 1996
31. Knopp RH: Niacin and hepatic failure. Ann Intern Med 111:769, 1989
32. Clementz GL, Holmes AW: Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroenterol 9:582-584, 1987
33. Mullin G, Greeson JK, Mitchel MC: Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 111:253-255, 1989